Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Boehringer Ingelheim
Johnson and Johnson
Merck
McKinsey

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR NESINA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nesina

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00856284 ↗ Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus Completed Takeda Phase 3 2009-03-01 The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
NCT01664624 ↗ Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes Completed AstraZeneca Phase 1 2012-07-01 The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
NCT01664624 ↗ Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes Completed Takeda Phase 1 2012-07-01 The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
NCT01945216 ↗ Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI" Completed Takeda 2010-07-08 The purpose of this study is to determine the safety and efficacy of long-term treatment with alogliptin (Nesina) in patients with type 2 diabetes mellitus who responded inadequately to diet therapy and exercise therapy alone, or a combination of diet therapy, exercise therapy, and α-glucosidase inhibitor. In addition, examining the safety and efficacy of alogliptin in patients with renal impairment, information on the appropriate dosage of alogliptin according to the severity of impaired renal function should be collected.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nesina

Condition Name

Condition Name for Nesina
Intervention Trials
Type 2 Diabetes Mellitus 5
Diabetes Mellitus, Type 2 4
Surveillance 3
Patients With Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nesina
Intervention Trials
Diabetes Mellitus, Type 2 14
Diabetes Mellitus 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nesina

Trials by Country

Trials by Country for Nesina
Location Trials
United States 57
Israel 9
Mexico 9
Hungary 8
Brazil 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nesina
Location Trials
Florida 3
California 3
Tennessee 2
Missouri 2
Nevada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nesina

Clinical Trial Phase

Clinical Trial Phase for Nesina
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 1 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nesina
Clinical Trial Phase Trials
Completed 11
Terminated 1
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nesina

Sponsor Name

Sponsor Name for Nesina
Sponsor Trials
Takeda 12
Kun-Ho Yoon 2
AstraZeneca 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nesina
Sponsor Trials
Industry 15
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Merck
Express Scripts
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.